Cell-based therapy technology classifications and translational challenges

Philosophical Transactions of the Royal Society B: Biological Sciences

Volumn 370, Issue 1680, 2015, Pages

  Mount, Natalie M ^a   Ward, Stephen J ^a   Kefalas, Panos ^a   Hyllner, Johan ^a,b  

^a GUY S HOSPITAL   (United Kingdom)

^b LINKÖPING UNIVERSITY   (Sweden)

Author keywords

Cell therapy; Clinical trial; Manufacturing; Regulation; Reimbursement; Translation

Indexed keywords

BIOTECHNOLOGY; CELLS AND CELL COMPONENTS; DISEASE TREATMENT; DRUG; RESEARCH WORK;

ANIMAL; BIOLOGICAL THERAPY; BIOTECHNOLOGY; CELL REPROGRAMMING TECHNIQUE; CLASSIFICATION; ECONOMICS; GENE VECTOR; HUMAN; RNA EDITING; TISSUE ENGINEERING; TRANSFORMED CELL LINE; TRANSLATIONAL RESEARCH; TRENDS;

ANIMALS; BIOTECHNOLOGY; CELL LINE, TRANSFORMED; CELL- AND TISSUE-BASED THERAPY; CELLULAR REPROGRAMMING TECHNIQUES; GENETIC VECTORS; HUMANS; RNA EDITING; TISSUE ENGINEERING; TRANSLATIONAL MEDICAL RESEARCH;

EID: 84942931759     PISSN: 09628436     EISSN: 14712970     Source Type: Journal    
DOI: 10.1098/rstb.2015.0017     Document Type: Review

References (86)

1. Becker AJ, McCulloch EA, Till JE. 1963 Cytological demonstration of the clonal nature of spleen colonies derived from transplanted mouse marrow cells. Nature 197, 452–454. (doi:10.1038/197452a0)
2. Weissman IL, Shizuru JA. 2008 The origins of the identification and isolation of hematopoietic stem cells, and their capability to induce donor-specific transplantation tolerance and treat autoimmune diseases. Blood 112, 3543–3553. (doi:10.1182/blood-2008-08-078220)
3. Bisson I, Green E, Sharpe M, Herbert C, Hyllner J, Mount N. 2015 Landscape of current and emerging cell therapy clinical trials in the UK: current status, comparison to global trends and future perspectives. Regen. Med. 10, 169–179. (doi:10.2217/rme.14.71)
4. Li MD, Atkins H, Bubela T. 2014 The global landscape of stem cell clinical trials. Regen. Med. 9, 27–39. (doi:10.2217/rme.13.80)
5. Maude SL et al. 2014 Chimeric antigen receptor T cells for sustained remissions in leukemia. N. Engl. J. Med. 371, 1507–1517. (doi:10.1056/NEJMoa1407222)
6. Lee DW et al. 2014 T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial. Lancet 6736, 1–12. (doi:10.1016/S0140-6736(14)61403-3)
7. Goff S, Berg P. 1976 Construction of hybrid viruses containing SV40 and lambda phage DNA segments and their propagation in cultured monkey cells. Cell 9, 695–705. (doi:10.1016/0092-8674(76)90133-1)
8. Cavazzana-Calvo M et al. 2000 Gene therapy of human severe combined immunodeficiency (SCID)- X1 disease. Science 288, 669–672. (doi:10.1126/science.288.5466.669)
9. Brittberg M, Lindahl A, Nilsson A, Ohlsson C, Isaksson O, Peterson L. 1994 Treatment of deep cartilage defects in the knee with autologous chondrocyte transplantation. N. Engl. J. Med. 331, 889–895. (doi:10.1056/NEJM199410063311401)
10. Green H, Kehinde O, Thomas J. 1979 Growth of cultured human epidermal cells into multiple epithelia suitable for grafting. Proc. Natl Acad. Sci. USA 76, 5665–5668. (doi:10.1073/pnas.76.11.5665)
11. McHeik JN, Barrault C, Levard G, Morel F, Bernard FX, Lecron JC. 2014 Epidermal healing in burns: autologous keratinocyte transplantation as a standard procedure: update and perspective. Plast. Reconstr. Surg. Glob. Open 2, e218. (doi:10.1097/GOX.0000000000000176)
12. Weissman IL. 2000 Translating stem and progenitor cell biology to the clinic: barriers and opportunities. Science 287, 1442–1446. (doi:10.1126/science.287.5457.1442)
13. Garbern JC, Lee RT. 2013 Cardiac stem cell therapy and the promise of heart regeneration. Cell Stem Cell 12, 689–698. (doi:10.1016/j.stem.2013.05.008)
14. Ellison GM et al. 2013 Adult c-kitpos cardiac stem cells are necessary and sufficient for functional cardiac regeneration and repair. Cell 154, 827–842. (doi:10.1016/j.cell.2013.07.039)
15. Huch M et al. 2015 Long-term culture of genomestable bipotent stem cells from adult human liver. Cell 160, 299–312. (doi:10.1016/j.cell.2014.11.050)
16. Stevanato L, Corteling RL, Stroemer P, Hope A, Heward J, Miljan EA, Sinden JD. 2009 c-MycERTAM transgene silencing in a genetically modified human neural stem cell line implanted into MCAo rodent brain. BMC Neurosci. 10, 86. (doi:10.1186/1471-2202-10-86)
17. Pollock K et al. 2006 A conditionally immortal clonal stem cell line from human cortical neuroepithelium for the treatment of ischemic stroke. Exp. Neurol. 199, 143–155. (doi:10.1016/j.expneurol.2005.12.011)
18. Qasim W, Thrasher AJ. 2014 Progress and prospects for engineered T cell therapies. Br. J. Haematol. 166, 818–829. (doi:10.1111/bjh.12981)
19. Cartier N et al. 2009 Hematopoietic stem cell gene therapy with a lentiviral vector in X-linked adrenoleukodystrophy. Science 326, 818–823. (doi:10.1126/science.1171242)
20. Cavazzana-Calvo M et al. 2010 Transfusion independence and HMGA2 activation after gene therapy of human beta-thalassaemia. Nature 467, 318–322. (doi:10.1038/nature09328)
21. Biffi A et al. 2013 Lentiviral hematopoietic stem cell gene therapy benefits metachromatic leukodystrophy. Science 341, 1233158. (doi:10.1126/science.1233158)
22. Aiuti A et al. 2013 Lentiviral hematopoietic stem cell gene therapy in patients with Wiskott-Aldrich syndrome. Science 341, 1233151. (doi:10.1126/science.1233151)
23. Naldini L. 2011 Ex vivo gene transfer and correction for cell-based therapies. Nat. Rev. Genet. 12, 301–315. (doi:10.1038/nrg2985)
24. Boura JS, Vance M, Yin W, Madeira C, Lobato da Silva C, Porada CD, Almeida-Porada G. 2014 Evaluation of gene delivery strategies to efficiently overexpress functional HLA-G on human bone marrow stromal cells. Mol. Ther. Methods Clin. Dev. 1, 14041. (doi:10.1038/mtm.2014.41)
25. Abrate A et al. 2014 Mesenchymal stem cells expressing therapeutic genes induce autochthonous prostate tumour regression. Eur. J. Cancer 50, 2478–2488. (doi:10.1016/j.ejca.2014.06.014)
26. Yin H, Kanasty RL, Eltoukhy AA, Vegas AJ, Dorkin JR, Anderson DG. 2014 Non-viral vectors for genebased therapy. Nat. Rev. Genet. 15, 541–555. (doi:10.1038/nrg3763)
27. Kay MA. 2011 State-of-the-art gene-based therapies: the road ahead. Nat. Rev. Genet. 12, 316–328. (doi:10.1038/nrg2971)
28. Hu YF, Dawkins JF, Cho HC, Marban E, Cingolani E. 2014 Biological pacemaker created by minimally invasive somatic reprogramming in pigs with complete heart block. Sci. Transl. Med. 6, p245-94. (doi:10.1126/scitranslmed.3008681)
29. Nathwani AC et al. 2014 Long-term safety and efficacy of factor IX gene therapy in hemophilia B. N. Engl. J. Med. 371, 1994–2004. (doi:10.1056/NEJMoa1407309)
30. Munch RC et al. 2015 Off-target-free gene delivery by affinity-purified receptor-targeted viral vectors. Nat. Commun. 6, 6246. (doi:10.1038/ncomms7246)
31. Doudna JA, Charpentier E. 2014 Genome editing. The new frontier of genome engineering with CRISPR-Cas9. Science 346, 1258096. (doi:10.1126/science.1258096)
32. Jinek M, Chylinski K, Fonfara I, Hauer M, Doudna JA, Charpentier E. 2012 A programmable dual-RNAguided DNA endonuclease in adaptive bacterial immunity. Science 337, 816–821. (doi:10.1126/science.1225829)
33. Tebas P et al. 2014 Gene editing of CCR5 in autologous CD4 T cells of persons infected with HIV. N. Engl. J. Med. 370, 901–910. (doi:10.1056/NEJMoa1300662)
34. Gurdon JB. 1962 The developmental capacity of nuclei taken from intestinal epithelium cells of feeding tadpoles. J. Embryol. Exp. Morphol. 10, 622–640.
35. Campbell KH, McWhir J, Ritchie WA, Wilmut I. 1996 Sheep cloned by nuclear transfer from a cultured cell line. Nature 380, 64–66. (doi:10.1038/380064a0)
36. Evans MJ, Kaufman MH. 1981 Establishment in culture of pluripotential cells from mouse embryos. Nature 292, 154–156. (doi:10.1038/292154a0)
37. Thomson JA, Itskovitz-Eldor J, Shapiro SS, Waknitz MA, Swiergiel JJ, Marshall VS, Jones JM. 1998 Embryonic stem cell lines derived from human blastocysts. Science 282, 1145–1147. (doi:10.1126/science.282.5391.1145)
38. Takahashi K, Yamanaka S. 2006 Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 126, 663–676. (doi:10.1016/j.cell.2006.07.024)
39. Takahashi K, Tanabe K, Ohnuki M, Narita M, Ichisaka T, Tomoda K, Yamanaka S. 2007 Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 131, 861–872. (doi:10.1016/j.cell.2007.11.019)
40. Yu J et al. 2007 Induced pluripotent stem cell lines derived from human somatic cells. Science 318, 1917–1920. (doi:10.1126/science.1151526)
41. Davis RL, Weintraub H, Lassar AB. 1987 Expression of a single transfected cDNA converts fibroblasts to myoblasts. Cell 51, 987–1000. (doi:10.1016/0092-8674(87)90585-X)
42. Vierbuchen T, Ostermeier A, Pang ZP, Kokubu Y, Sudhof TC, Wernig M. 2010 Direct conversion of fibroblasts to functional neurons by defined factors. Nature 463, 1035–1041. (doi:10.1038/nature08797)
43. Wapinski OL et al. 2013 Hierarchical mechanisms for direct reprogramming of fibroblasts to neurons. Cell 155, 621–635. (doi:10.1016/j.cell.2013.09.028)
44. Xu J, Du Y, Deng H. 2015 Direct lineage reprogramming: strategies, mechanisms, and applications. Cell Stem Cell 16, 119–134. (doi:10.1016/j.stem.2015.01.013)
45. Turner M et al. 2013 Toward the development of a global induced pluripotent stem cell library. Cell Stem Cell 13, 382–384. (doi:10.1016/j.stem.2013.08.003)
46. Gourraud PA, Gilson L, Girard M, Peschanski M. 2012 The role of human leukocyte antigen matching in the development of multiethnic ‘haplobank’ of induced pluripotent stem cell lines. Stem Cells 30, 180–186. (doi:10.1002/stem.772)
47. Murphy SV, Atala A. 2014 3D bioprinting of tissues and organs. Nat. Biotechnol. 32, 773–785. (doi:10.1038/nbt.2958)
48. Wegst UG, Bai H, Saiz E, Tomsia AP, Ritchie RO. 2015 Bioinspired structural materials. Nat. Mater. 14, 23–36. (doi:10.1038/nmat4089)
49. Smith BD, Grande DA. 2015 The current state of scaffolds for musculoskeletal regenerative applications. Nat. Rev. Rheumatol. 11, 213–222. (doi:10.1038/nrrheum.2015.27)
50. Ringe J, Sittinger M. 2014 Regenerative medicine: selecting the right biological scaffold for tissue engineering. Nat. Rev. Rheumatol. 10, 388–389. (doi:10.1038/nrrheum.2014.79)
51. Pedersen RA, Mascetti V, Mendjan S. 2012 Synthetic organs for regenerative medicine. Cell Stem Cell 10, 646–647. (doi:10.1016/j.stem.2012.04.003)
52. Sasai Y. 2013 Next-generation regenerative medicine: organogenesis from stem cells in 3D culture. Cell Stem Cell 12, 520–530. (doi:10.1016/j.stem.2013.04.009)
53. Bryant LM et al. 2013 Lessons learnt from the clinical development and market authorisation of Glybera. Hum. Gene Ther. Clin. Dev. 24, 55–64. (doi:10.1089/humc.2013.087)
54. Da Cruz LCF, Ahmado A, Greenwood J, Coffey P. 2007 RPE transplantation and its role in retinal disease. Prog. Retin. Eye Res. 26, 598–635. (doi:10.1016/j.preteyeres.2007.07.001)
55. Schwartz SD et al. 2015 Human embryonic stem cell-derived retinal pigment epithelium in patients with age-related macular degeneration and Stargardt’s macular dystrophy: follow-up of two open-label phase 1/2 studies. Lancet 385, 509–516. (doi:10.1016/S0140-6736(14)61376-3)
56. Food and Drug Administration. 2013 Considerations for the design of early-phase clinical trials of cellular and gene therapy products. Draft guidance for industry. Rockville, MD: Center for Biologics Evaluation and Research, FDA.
57. European Medicines Agency. 2009 Guideline on follow-up of patients administered with gene therapy medicinal products. EMEA/CHMP/GTWP/60436/2007. London, UK: Committee for Medicinal Products for Human Use.
58. Herttuala SY. 2015 Glybera’s Second Act: the curtain rises on the high cost of therapy. Mol. Ther. 23, 217–218. (doi:10.1038/mt.2014.248)
59. Herberts CA, Kwa MS, Hermsen PH. 2011 Risk factors in the development of stem cell therapy. J. Transl. Med. 9, 29–43. (doi:10.1186/1479-5876-9-29)
60. Sharpe ME, Morton D, Rossi AN. 2012 Nonclinical safety strategies for stem cell therapies. Toxicol. Appl. Pharmacol. 3, 223–231. (doi:10.1016/j.taap.2012.05.007)
61. Casucci M, Hawkins RE, Dotti G, Bondanza A. 2015 Overcoming the toxicity hurdles of genetically targeted T cells. Cancer Immunol. Immunother. 64, 123–130. (doi:10.1007/s00262-014-1641-9)
62. Hacein-Bey-Abina S et al. 2003 LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science 302, 415–419. (doi:10.1126/science.1088547)
63. Zhang L, Thrasher AJ, Gaspar HB. 2013 Current progress on gene therapy for primary immunodeficiencies. Gene Ther. 20, 963–969. (doi:10.1038/gt.2013.21)
64. Lee AS, Tang C, Rao MS, Weissman IL, Wu JC. 2013 Tumorigenicity as a clinical hurdle for pluripotent stem cell therapies. Nat. Med. 19, 998–1004. (doi:10.1038/nm.3267)
65. Kawamata S, Kanemura H, Sakai N, Takahashi M, Go MJ. 2015 Design of a tumorigenicity test for induced pluripotent stem cell (iPSC) derived cell product. J. Clin. Med. 4 159–171. (doi:10.3390/jcm4010159)
66. Almeida PE, Ransohoff JD, Nahid MA, Wu JC. 2013 Immunogenicity of pluripotent stem cells and their derivatives. Circ. Res. 112, 549–561. (doi:10.1161/CIRCRESAHA.111.249243)
67. Buja LM, Vela D. 2010 Immunologic and inflammatory reactions to exogenous stem cells. J. Am. Coll. Cardiol. 56, 1693–1700. (doi:10.1016/j.jacc.2010.06.041)
68. Fabre D, Kold F, Fadel E, Mercier O, Mussot S, Le Chevalier T, Dartevelle P. 2013 Successful tracheal replacement in humans using autologous tissues: an 8-year experience. Ann. Thorac. Surg. 96, 1146–1155. (doi:10.1016/j.athoracsur.2013.05.073)
69. Dodson BP, Levine AD. 2015 Challenges in the translation and commercialization of cell therapies. BMC Biotechnol. 15, 70.
70. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH). 2005 Q9 Quality Risk Management. Harmonised Tripartite Guideline. Geneva, Switzerland: ICH.
71. European Commission. 2008 EudraLex: the rules governing medicinal products in the European Union, Volume 4, Good Manufacturing Practice Guidelines. Annex 1: Manufacture of Sterile Medicinal Products. Brussels: EU.
72. Csaszar E, Chen K, Caldwell J, Chan W, Zandstra PW. 2014 Real-time monitoring and control of soluble signaling factors enables enhanced progenitor cell outputs from human cord blood stem cell cultures. Biotechnol. Bioeng. 111, 1258–1264. (doi:10.1002/bit.25163)
73. Baradez M-O, Marshall D. 2011 The use of multidimensional image-based analysis to accurately monitor cell growth in 3D bioreactor culture. PLoS ONE 6, e26104. (doi:10.1371/journal.pone.0026104)
74. Maciulaitis R, D’Apote L, Buchanan A, Pioppo L, Schneider CK. 2012 Clinical development of advanced therapy medicinal products in Europe: evidence that regulators must be proactive. Mol. Ther. 20, 479–482. (doi:10.1038/mt.2012.13)
75. Flory E, Reinhardt J. 2013 European regulatory tools for advanced therapy medicinal products. Transfus. Med. Hemother. 6, 409–412. (doi:10.1159/000356364)
76. Hara A, Sato D, Sahara Y. 2014 New governmental regulatory system for stem cell-based therapies in Japan. Ther. Innov. Reg. Sci. 48, 681–688. (doi:10.1177/2168479014526877)
77. Sherman RE, Li J, Shapley S, Robb M, Woodcock J. 2013 Expediting drug development—the FDA’s new ‘breakthrough therapy’ designation. N. Engl. J. Med. 369, 1877–1880. (doi:10.1056/NEJMp1311439)
78. Eichler HG et al. 2012 Adaptive licensing: taking the next step in the evolution of drug approval. Clin. Pharmacol. Ther. 91, 426–437. (doi:10.1038/clpt.2011.345)
79. Gregson N, Sparrowhawk K, Mauskopf J, Paul J. 2005 Pricing medicines: theory and practice, challenges and opportunities. Nat. Rev. Drug Discov. 4, 121–130. (doi:10.1038/nrd1633)
80. van der Vossen AC, Nachtnebel A, Wild C. 2013 Marketing authorisations under exceptional circumstances for oncology drugs: an analysis of approval and reimbursement decisions of four drugs. HTA-Projektbericht 65. Vienna, Austria: Ludwig Boltzmann Institut fuer Health Technology Assessment.
81. Levaggi R. 2014 Pricing schemes for new drugs: a welfare analysis. Soc. Sci. Med. 102, 69–73. (doi:10.1016/j.socscimed.2013.11.048)
82. Kefalas P. 2014 UK Market Access Considerations for the Cell Therapy Industry. London, UK: Cell Therapy Catapult. See https://ct.catapult.org.uk/whitepapersand-resources (accessed on 16 Feb 2015).
83. Barros 2010 Pharmaceutical policies in European countries. Adv. Health Econ. Health Serv. Res. 22, 3–27. (doi:10.1108/S0731-2199(2010)0000022004)
84. National Institute for Health and Care Excellence (NICE). 2013 Guide to the methods of technology appraisal. Process and methods guide. See http://publications.nice.org.uk/pmg9.
85. Drummond M, de Pouvourville G, Jones E, Haig J, Saba G, Cawston H. 2014 A comparative analysis of two contrasting European approaches for rewarding the value added by drugs for cancer: England versus France. Pharmacoeconomics 32, 509–520. (doi:10.1007/s40273-014-0144-z)
86. National Institute for Health and Care Excellence (NICE). 2013 Highly specialised technologies guidance. See https://www.nice.org.uk/about/whatwe-do/our-programmes/nice-guidance/nice-highlyspecialised-technologies-guidance (accessed 16 Feb 2015).